In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Mercury poisoning

This article was originally published in The Rose Sheet

Executive Summary

Mercury poisoning: Texas and New Mexico state health departments and San Diego County Health Department investigating three cases of mercury poisoning related to use of Crema de Belleza-Manning, a beauty cream manufactured and sold in Mexico, according to the Center for Disease Control's May 17 Morbidity and Mortality Weekly Report. The cream, which contains calomel or mercurous chloride, was found to contain 6%-8% mercury by weight and was implicated as the source of mercury in the three cases, the report states. The Texas Department of Health circulated a May 16 advisory letter including an attachment of the MMWR report to the health departments of the border states as well as a separate press release recommending discontinuation of the use of the cream, according to MMWR. FDA noted that currently, there are no plans to "pull control away from the states," although the agency stressed that it would be willing to intercede if the products were found to be widely distributed in the U.S...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts